Clifford A. Hudis, MD: Paclitaxel Beats Out Newer Agents in the Treatment of Advanced Breast Cancer
Description: Dr. Cliff Hudis discusses paclitaxel beat two newer chemotherapies—nab-paclitaxel (Abraxane) and ixabepilone (Ixempra)—in the treatment of metastatic breast cancer patients who have not had prior systemic therapies. Paclitaxel fared better in terms of both efficacy and safety compared to the newer agents at the designated doses.
This interview was filmed at the American Society of Clinical Oncology Annual Meeting in Chicago 2012.
Clifford A. Hudis, MD is the Chief, Breast Cancer Medicine at Memorial Sloan-Kettering Cancer Center in New York City. He is a medical oncologist with research interests in all areas of care related to breast cancer. His clinical practice is devoted solely to the treatment of patients with breast cancer; and his research is focused on prevention of the disease, prevention of recurrence after surgery, and treatment of recurrences.
Shared By : vitaloptions
Posted on : 07/12/12
Added : 6 years ago